Are you skipping that doctor visit or pill you need? – CBS News

With medical costs continuing to rise along with the uncertainty about the future of health insurance coverage, new research shows more Americans are going without the health care they need.

A survey released Wednesday from Bankrate.com found that one in four American families have not sought medical care because they couldn't afford it. Thirteen percent of respondents had no insurance, while the rest had a mix of employer-sponsored, individual and Medicaid coverage. The bulk of uninsured respondents were millennials. Younger, healthier people traditionally go without coverage.

However, "Even insured people found co-pays and deductibles far less affordable than they expected," said Robin Saks Frankel, credit card analyst at Bankrate.com

Two years ago, a Kaiser Family Foundation study found that only three in five households have enough set aside to meet an individual deductible of $1,200 or a family deductible of $2,400. Only about half of U.S. households had enough money to cover higher deductibles than those.

Play Video

President Obama's former economic adviser Austan Goolsbee joins CBSN to discuss the costs of the American Health Care Act, the GOP's replacement ...

Health care advocates and economists agree that forgoing health care can have devastating long-term consequences. It can mean patients get sicker and require even more expensive treatment when they end up in the emergency room. These types of unexpected medical bills can lead to a huge financial burden for the patient that could take years to pay off, said Frankel.

If you're struggling with medical costs or skipping the care you need, here are four strategies that may help make your health care more affordable.

Schedule your annual physical. If you have insurance, there's no reason to skip this important appointment. Under the Affordable Care Act, annual physicals are 100 percent covered. That means no co-pay, and your deductible doesn't have to be met beforehand. Spotting medical problems while they're small can prevent big problems (and bigger medical bills) down the road. If your physical yields some unwelcome results, you can talk to your doctor about the cost of future diagnostics and care. See the next item.

Don't be afraid to negotiate. If you're due for an expensive test, procedure or a series of doctor visits, be sure to ask about the price and your out-of-pocket costs ahead of time. You can research the costs at various labs and facilities in your area at websites such as Healthcare Bluebook. Then talk to your doctor or insurer about what you've found and how you can get a lower price. Separately, your doctor may offer payment plans or discounts for extended treatments. Be sure to ask.

Play Video

President Trump is pushing Republican senators to get on board with the legislation passed by the House to roll back Obamacare, but key Republica...

When you do receive a medical bill, review it carefully. Always make sure it's itemized, and check for errors. All health care providers use special billing codes, so mistakes can easily creep in. If you suspect you've been overcharged or mischarged for something, check with your provider and your insurer.

Pay less for prescription drugs. For many people, medication is the biggest health expense. Consider ordering regular, long-term medicines in bulk for lower prices. For less frequent medications, shop for the best prices in your area using comparison websites such as GoodRx. And always discuss any possible generic alternative with your doctor. Low-income patients should check with drug companies directly for any prescription relief programs they may offer, especially for expensive specialized drugs.

Sign up for your FSA or HSA. If your employer offers a Flexible Spending Account or Health Savings Account, be sure to take advantage. For an FSA, your contributions are made pretax, and the money can be used, among other things, for co-pays and health expenses before your deductible. HSAs are used if you have a qualifying high-deductible insurance plan. Contributions are also pretax, and no tax is paid when money is withdrawn for qualified medical expenses. Employers often contribute to workers' accounts as an incentive to get them to sign up for high-deductible health plans.

2017 CBS Interactive Inc.. All Rights Reserved.

Go here to see the original:

Are you skipping that doctor visit or pill you need? - CBS News

With Breast Cancer, the Best Treatment May Be No Treatment – WIRED

F0;).p!x)$[Q$IH @R9=g9MI6"2HXIVT"Df="3EO~z<[=+jx_>e'2}Bxtq%9;v~/2ez^ 9v$y6G'x.mV8&W/|vxLgZYz!0mh7/dJ]glF#9M}w`l{^*M.IxZQsfA-xA<7Xr6cKhm[7-^JV/5KK_k<^Z6w3mF{8I?W6gZ1QM4`ie7VA6E48<[@9G|C,:Gno$y|98=G*F96qtBL&qts.c{0F>?_@-]VP,NO`LpHAn<}m%M~5w`KynoB7NWvlbh)w],+FtW7qenK0#V,QgGosD?^VLGU/tqjCm 5:UoP71zkY#c8y5&]rl^AlF8K>2.XT/ks@W [MAt.M3`<{d3Mogc/)=^ugmYV:)Y>?j.4;0ka3`)|h. ?ADk9=A#)A_i!Y:{xv"+\ .SJ2OGv?uz#hR}88z%yWgrvX}Z] ##-CKTDzsp{quo?:yVpt4amG%dzuog'BT~ eNXT<":?$Cj0ji?LJoQ!)960qo76 , Oh#`rq.Ysu|@j!wMAe>2@?@L:i0@EY_yEF4[x"4a=I<[-oIg'#Q*AFh]>yg:?;Fy>7FZ.A$u T*bti=qzyt]Cae~ 4]oyY};@9XaA-!l?P}s#Q)-]QohoG7kaIzO?FTel(d> C6|Z hn6z1,F@[$lp|.^bN>;g1plKr7n#Ik(9{[b77HO"CY 6J RBMAx"5 YQQS<`y/Q D!ub0k,mv7:1A mv/:;RFAKKQ+x1Fv}^zQXR-}CBe>n5hG*p}!|@58b0Se8YQ j' fu@`1vq]o lOYV=y& TDW~FG9MyLn`FaCS$&' k#a^$():s9)f..Lp,uIqq@HRj:n"$qcdh::r'i6S) -M'*8apCr2s~X/+x]cjhnlW-HV2yMxH_4M 8|Hk AF<0; |qYYUb'fzYZ6wM*-!=KH@Xy;]nv?[fCuG8/b;)e.UY>5Pub5%HKr60e@6|S gs(*Vp/Sz*IIP6w'WyVeu-+@m`97I@f= & S&ff<)T1xX-rXE%|Rf:)fS;}jq#5XwcdyW4C Z-x[AtEpI:69]=wzAL=B&_qUM0IEd F, D?YL2G0? sy8rD'j?ONKt$DK9Qvf:4@~4`1*7tSc`[MT6=8A64Vg>/PX{/U?q (/P({C0?&@` P(_qVa7-@c@?qC`ys87uq0q484Vc@0zGGxoQ PWgX,a#uuDui`[qaQuy$ktD*= ?]@aCf//Q`pMH9//Q`{XH0q`8;m[IlcGl6Xt16m,_k#ZVjex1<7Zge8_yT1,<&c2J9*@EI2yg|0S`(w`f~Nv( `!gZ02e^"[&cna fL-1 #.`y -`z0(KqeG csr18SX0@(.K SKcyoi.S.)~%IsQxk@?)Ep;5u*;b~x`gm@U@ OuJ3?IMc4i?rQIL&x[1S%@^3I`"I}wBx=4hwP:1["V624/4 %C(oznQ7HP78B1 w+Go$^JA[*@|iD/$*[4&,&R9Dp)*SBjN (F&3IgPXK:v3~G!n;>>L`.n?NQ'=`tzOqce;D2S IS{Bk@NU)wv- pVB)T4knSyK' j7K-u4y:U/O[xZ>Z{;ajOZ~`eB'jxytIY#S cPmlPmll 7a-J)/6EHeZk)8)ov=AZay`@b:01iCB3P=GE95PiE8 Q#2*dj@U0^HuSiXJ!"f;(F&q$+|9Qyu&fa#)%!-$eyN(4)wl:KlASegPpRNIsoS<%0%1w~tQ<1ZqHi/T;k^M 59[l$8&`='lD.&-|QQ8/T&A$87@.q6|Vr*b29(E4(BzlG3" !HO e@UQ-.G/4Bf}K X+=01 NM~| U2l?MzUzTG5vVLLnotI qiS m3Vl X^"GAF9YA#~hp`u}OvtNIWa~dHX_SxAVD;,rR]N)=PL(zO;4Pt[66 V-ZkI&Bfg"/!r7gI6Uo7Yd 4x~z-j 0l}/Sb{]B7~z:zuqqvw-/mEC6[b;5oW{^K,kDGJ~{V2^nA8N* l{XvjXj-`#tBu5L1m#EwEFA-"])l@HG`}hS4hG&. mSK#[|snI&]y2uMLk]/ijx`K1|tP01Q[sm-,wO;$rgY29V,Ljrn* [Ke!m6X:xnl~~llXW|m3wdc=SxK`kY|h}2t*hF8iW]jaY{`Z.#g'`>(+jx8<7`d5m qA7:]}5Q;cM~o|m9]VP/YYI5X0N*c3YvA,}S20lU,Iyfry`h/,ho5#v$^ja292Lm%i6?r;4.#78WFR'Q|$B;bU+[>:OmE?7X;bdt?x!h9]X?-&)~,2@cK%~sx%cn&&M.ctLS#M$&d0aeJ1II-1hwFl7:x8:Ltf'"W(yxQg%;13GD:O6eE!i.7n;hWS~RNz_#!_?;eg}L):q)n&5#?pr>6C$xlYfq}?wd_m wwK:Vo;}8|-[W'L0L}iFG}K{BV"~v"'NtFQ u"RoE =S=u3_i?oFiI"pF8/pEo"k0D@L.D,^p[ROey& G7]U7c7nkx.&Q) Oe54m"=EcG")k} V2A.4o%_?$pG28m0xS'tX!v-<` wzYtqNg?l'$*YX;{G4&Hz2!^ Khs76Pl*C(y X6c`Toh)hm8~/X 1CNL@A:zvfK>Y3klt~STm=N'-STwi'@Oo|E0d`v00:qN8hgZcxZ"b%{K5G/o:n oUmmz([>A7h7M; zX=_Vn *LM77~-jY~yR;b4tu[VktgR=5Ylnk x"7_0I-Gh/zN;(ylm77aU<}"y$0C4I nW$S /`,y&3Q]$0pg(1HP4nJ08rq @jbe=V*UN-/ 4U[

Read the original post:

With Breast Cancer, the Best Treatment May Be No Treatment - WIRED

How genetic engineering could boost biofuel production in Africa and Latin America – Genetic Literacy Project

Bioenergy production techniques that are already available could be used to supply up to 30 percent of the worlds energy by 2050, according to a 2015 report by The Scientific Committee on Problems of the Environment (SCOPE), a global network of scientists from 24 countries that reviews scientific knowledge on the environment.

To find out why scientists are so optimistic about biofuel production in the developing world, SciDev.Net spoke with Glaucia Mendes Souza, researcher at the Chemistry Institute of the University of So Paulo.

Souza is also coordinator of the Bioenergy Research Program at the Brazilian research foundation FAPESP, and co-editor of the report.

What is the potential for expanding biofuel production in Latin America and Africa?

Huge! There are at least 500 million hectares of land available for biofuel production around the world. Much of that is in Latin America and sub-Saharan Africa, and is currently being used for low-intensity grazing.

What are the main scientific and technological advances related to biofuel production in Brazil?

Thanks to the ethanol programme and research carried out by the private sector, as well as public research entities, Brazil has obtained genetically improved varieties of sugar cane and managed to increase its productivity from 49 tonnes per hectare in 1970 to 85 tons per hectare in 2010.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: Q&A: Boosting bioenergy in Africa and Latin America

Read the original:

How genetic engineering could boost biofuel production in Africa and Latin America - Genetic Literacy Project

VBL Wins $2.5M Grant to Progress Pivotal-Stage Anticancer Gene Therapy – Genetic Engineering & Biotechnology News

VBL Therapeutics won an ILS8.75 (approximately $2.5 million) grant from the Israel Innovation Authority to support continued clinical development of the firms lead Phase III-stage gene therapy ofranergene obadenovec (VB-111). The antiangiogenic candidate is being evaluated in a pivotal Phase III GLOBE study in patients with recurrent glioblastoma (rGBM) under an FDA Special Protocol Assessment. Phase II studies with VB-111 have previously been carried out in patients with platinum-resistant ovarian cancer and differentiated thyroid cancer indications.The gene therapy is administered as an IV infusion once every two months.

VBL says the grant will fund clinical trials and development activities for the 2017 calendar year. The continuous financial support for the VB-111 program is an important contribution to our ability to execute on our plans into 2019, as we prepare for the commercialization of VB-111 and establish our new manufacturing site, commented Dror Harats, M.D., CEO at VBL Therapeutics. We believe this nondilutive grant for the VB-111 program underscores the confidence that the Innovation Authority has in our technology and its potential for commercialization.

Vascular Biogenics Ltd., operating as VBL Therapeutics, is developing a portfolio of anticancer and anti-inflammatory programs based on its proprietary Vascular Targeting System (VTS) and lecinoxoidplatforms. VB-111 is an antiangiogenic, adenovirus 5 vector-based gene therapy developed using the VTS technology.

VBL is, in addition, developing a series of orally available, small-molecule lecinoxoid compounds that exhibit immune modulating anti-inflammatory properties for treating chronic immune-related conditions. An exploratory Phase II study with lead lecinoxoid candidate VB-201 indicated that the compound reduces vascular inflammation in atherosclerosis. DuringApril, VBL separately presented data from a retrospective analysis of Phase II studies indicating that oral administration of VB-201 reduces levels of liver enzymes. The firm said the data support the potential use of lecinoxoids for liver-related indications, including nonalcoholic steatohepatitis (NASH).

Read more here:

VBL Wins $2.5M Grant to Progress Pivotal-Stage Anticancer Gene Therapy - Genetic Engineering & Biotechnology News

Breakthrough Gene Therapy Approach Raises Hopes For Patients With Blood Cancer – Wall Street Pit

Multiple myeloma (also known as plasma cell myeloma) is a cancer of plasma cells, specifically, the kind of white blood cell that produces antibodies to help fight infection. Based on statistics from the National Cancer Institute, its currently one of the fastest growing cancer types the second for men and the third for women. In the U.S. alone, it is estimated that 30,280 new cases will be diagnosed this year, and 12,590 cases will turn out to be fatal.

Since the year 2000, a total of nine drugs have been approved as treatments for multiple myeloma. But the drugs cant be considered as cures because even with the treatment, only around 50% of patients live up to 5 years after being diagnosed with the disease. Thankfully, that might soon change.

A few days ago, at the American Society of Clinical Oncology conference held in Chicago, doctors reported about the success of a new treatment for multiple myeloma called CAR-T (short for Chimeric Antigen Receptor-T) therapy an individualized treatment that makes use of blood filtering and genetic reprogramming.

The process works by removing immune system cells called T cells from a patients blood, after which, the filtered blood is modified to contain a cancer-targeting gene, then re-injected into the patient to seek and destroy cancer cells. Its being called a living drug a one-time treatment designed to permanently alter cells that multiply in the body, turning those cells into an army of cancer-fighting cells.

In the clinical trial led by Dr. Wanhong Zhao associate director of hematology at The Second Affiliated Hospital of Xian Jiaotong University in Xian, China 33 out of 35 patients responded positively within two months of the treatment, with some patients responding as early as 10 days after the first injection (three separate injections were given in a span of more than a week).

So far, 19 of the patients are currently well beyond the timeframe needed for full efficacy assessment by the International Myeloma Working Group (IMWG) consensus. In other words, it is now reasonable to conclude if complete remission has been achieved in a patient or not. And the results are: 14 are now in complete remission, 4 have achieved very good partial remission, and 1 is in partial remission.

In terms of side effects, most experienced typical ones such as fever, low blood pressure and difficulty in breathing. Only 2 patients experienced severe side effects, though such were temporary and easily manageable.

As Dr. Zhao said: Although recent advances in chemotherapy have prolonged life expectancy in multiple myeloma, this cancer remains incurable. It appears that with this novel immunotherapy there may be a chance for cure in multiple myeloma, but we will need to follow patients much longer to confirm that.

Following the success of this small clinical trial, the researchers are now planning a bigger trial involving 100 patients. Early next year, they are also planning a similar run in the U.S.

Read more from the original source:

Breakthrough Gene Therapy Approach Raises Hopes For Patients With Blood Cancer - Wall Street Pit

Nationwide Children’s spins out fourth gene therapy company this one is staying in Central Ohio – Columbus Business First


Columbus Business First
Nationwide Children's spins out fourth gene therapy company this one is staying in Central Ohio
Columbus Business First
Nationwide Children's Hospital has spun out its fourth gene therapy startup to result from decades of research and millions in investment in manufacturing equipment and commercialization personnel.

Read the rest here:

Nationwide Children's spins out fourth gene therapy company this one is staying in Central Ohio - Columbus Business First

News from the AAN Annual Meeting: Gene Therapy Found to Benefit Infants with SMA Type 1 in Open-Label Trial – LWW Journals

Collins, Thomas R.

doi: 10.1097/01.NT.0000520852.35562.83

Features

In a new gene therapy trial, infants with spinal muscular atrophy survived longer without adverse events and achieved developmental milestones. Independent experts said the therapy should be studied and compared with the recently-approved drug, nusinersen.

BOSTON All 15 infants treated with gene therapy for spinal muscular atrophy type 1 (SMA-1) survived past the age at which 75 percent of untreated infants typically die or need at least 16 hours a day of ventilation support, according to results of an open-label phase 1 trial reported here in April at the AAN Annual Meeting.

The event-free survival of the infants to at least 13.6 months shows the promise of the proprietary gene therapy known as AVXS-101, for Avexis, the Illinois-based manufacturer that funded the study.

The drug uses an adeno-associated virus 9 AAV9 to deliver a fully functioning survival motor neuron gene to the patient's cells.

Researchers also found that all nine infants born at least 20 months before the January data cut-off reached the 20-months' time point. All of the patients in the trial are alive, and only one has required 16 or more hours per day of ventilator support at 28.8 months, according to the researchers.

The United States Food and Drug Administration (FDA) granted the drug breakthrough therapy status, which will mean faster review, in July.

Jerry R. Mendell, MD, FAAN, the principal investigator of the current study, said SMA-1 is nearly always fatal for children. Dr. Mendell, who conducted the first gene therapy studies on the treatment and developed the neuromuscular gene therapy program at Nationwide Children's Hospital in Columbus, OH, noted that a 2014 study in Neurology, conducted to establish the natural history against which potential therapies could be measured, found that only 25 percent of children with SMA-1 survive without permanent ventilation beyond 13.5 months. And only 8 percent of untreated infants live beyond 20 months.

In the current study, 12 of the 15 children were given the high dose of the drug. All of these infants have reached at least one milestone, and most have achieved several milestones, such as bringing their hands to their mouths, head control, and sitting. Two children stand and walk independently, and eight can talk.

These are milestones that are essentially never achieved in untreated children, said Dr. Mendell, who reported he has no financial interest in the drug.

None of them ever learn to talk and as they approach their death march, they can no longer feed except by G-tube and they basically live in a vegetative state, he said. And all that has changed dramatically.

Dr. Mendell emphasized the importance of early treatment. The two best patients in our clinical trial were those who were treated very early, and they very rapidly reversed their course; they are now walking, he said. Many of the patients in the trial were treated early because they have a family history [for SMA] and were recognized prenatally. That is what facilitated the study and also what will make a difference in the long run.

He added: I'm hoping the results of this study will allow for newborn-screening for this disease. That will provide a pathway for early treatment.

Last year, the FDA approved the new SMA drug nusinersen, an antisense oligonucleotide therapy, which uses targeted RNA binding to boost production of a protein in which SMA patients are deficient. Dr. Mendell said it's possible that the two drugs could work well together, although this hasn't been evaluated yet.

What we all wonder about on the gene therapy side and on the oligonucleotide side is whether these treatments could be complementary, he said. We'll know the answer to that because some of our patients have requested opportunity to move to nusinersen.

He noted that is an option for patients after their two-year enrollment commitment is reached.

In a review of the abstract, Brent L. Fogel, MD, PhD, FAAN, associate professor of neurology and human genetics at the University of California, Los Angeles, said the results sound promising, and he agreed that the therapy should be compared with nusinersen.

Given the recent success of the FDA-approved antisense oligonucleotide therapies which increase production of SMN protein by altering the splicing of the endogenous SMN2 gene, rather than replacing the damaged SMN1 gene it would be important to compare the risk and benefit between the two approaches to determine the optimal treatment for patients with SMA, who previously had none at all, he said.

He said that other clinical questions remain, as well. It would be of key interest to know what cells the virus is targeting, the resulting gene expression initially and whether that is maintained, and if any side effects are observed as the patients are followed over time, Dr. Fogel said. This would have implications for similar future therapies in other neurogenetic disorders.

Kathryn J. Swoboda, MD, director of the neurogenetics program at the Massachusetts General Hospital for Children, who was a site leader in the multi-center trial on nusinersen, noted that the evidence of gene therapy's efficacy is limited in scope, at least for now.

It's a viral-derived vector, she said, referring to the AAV-9 used in the gene therapy trial. It's a common virus that people are ultimately exposed to so they produce antibodies with time. So the proof that it works is only in babies right now, she said

If you take a young baby with SMA, those are where the phenomenal results are. Even if you took a 9-month-old or an 8-month-old or a 7-month-old with a severe form of disease, it didn't do much, because by then they've already had devastating loss of motor neurons. So we don't know how this would be tolerated in older patients and adults, and we don't have the capacity to make enough virus to deliver it to those patients at this point, and so it's going to take some additional time to do those studies.

The approval of nusinersen could complicate the future of trials on gene therapy, she said.

You've already got an approved drug and how do you design those trials? Do you say they can't get a drug we know might help them? And what if the therapy for gene therapy doesn't work? A back-up plan to start the approved therapy later could mean it might to be too late to respond, she said.

I think there's a lot to think about from an ethical perspective.

News of new therapies for the disease has drawn tremendous demand for SMA treatment from around the world, she said.

We've gotten calls from parents of newborns, prenatal cases, all the way up to 70-year-old patients who want something because it's a progressive disease, she said. And even though it's slowly progressive after a certain point, you're still losing something continuously over time.... They don't even care if it's a major improvement. They just want to stay where they are.

Nonetheless, the path forward is not clear, she said.

Does this cure? Do we have a cure yet? No. We have a really promising set of therapies that are so above anything we've seen for neurodegeneration that it's tremendously exciting. But it doesn't mean that it makes it easy to figure out how to do this.

. AAN Annual Meeting Abstract CT.003: Mendell J, Al-Zaidy SA, Shell R, et al. AVXS-101 phase 1 gene therapy clinical trial in SMA type 1: Event free survival and achievement of developmental milestones. http://bit.ly/genetherapy-abstract.

. AAN Annual Meeting Abstract CCI.002: Kuntz N, Farwell W, Zhong ZJ, et al, on behalf of the ENDEAR Study Group. Nusinersen in infants diagnosed with spinal muscular atrophy (SMA): Study design and initial interim efficacy and safety findings from the phase 3 international ENDEAR study. http://bit.ly/nusinersen-abstract

. Sign up for the video link to the plenary here: http://aan.informz.net/AAN/pages/17_AMOD_Form.

View post:

News from the AAN Annual Meeting: Gene Therapy Found to Benefit Infants with SMA Type 1 in Open-Label Trial - LWW Journals

Elon Musk: The Rocket That Will Eventually Take Humans to the Moon Will Launch in 4 Months – Futurism

In Brief In a tweet today, Elon Musk said that the highly anticipated Falcon Heavy launch would take place within the next few months. The rocket will transport the first space tourists, and it could take humanity farther in space than ever before.

Elon Musk is having a rather goodweek. He put on an excellent showing at Teslas annual shareholders meeting,and today, the news broke that Teslas stock price has surged. The company is listed on the Fortune 500 list for the first time ever. But of course, we cannot forget about another of Musks revolutionary outfits: SpaceX.

Musks space company has a number of milestone eventplanned for the coming months. Case in point, afew moments ago, a question from a Twitter user sparked an update from Musk on the companys plans to launch the Falcon Heavy, SpaceXs massive rocket that will one day take humans to the Moon.

In the tweet, Musk confirmedthat we will beseeing the rocket launch in just four months, at theend of the summer.

The Falcon Heavy will be the most powerful rocket in the world, capable of launching 54 metric tons (119,000 lb) of cargo and crew into space. The rocket will be used to boost the first space tourists to the Moon in a launch expected to take place in 2018. The entire journey is expected to take about six to seven days.

The Falcon Heavy will likely also play a role in preparing SpaceX for the highly anticipated first manned missions to Mars, set to happen by 2025.

We look forward to the upcoming launch and all the promise that its success will bring.

Original post:

Elon Musk: The Rocket That Will Eventually Take Humans to the Moon Will Launch in 4 Months - Futurism

New Discovery of the Oldest Known Human Remains Will Change the Narrative of Human Evolution – Futurism

In BriefScientists have just discovered the oldest human fossils inMorocco. This find alters the narrative of human origins and helpsfill in missing details in our evolution as a species. Rediscovering Ourselves

On Wednesday, scientists reported they had discovered the oldest known remains of Homo sapiens in Morocco.The bones and other remains are approximately 300,000 years old. This revelation provides new insights into the origins of humankind: a consequence of such findings would be that human beingsevolved earlier than had previously believed. The fossils also indicate that despite fundamental differences in the brains of modern humans and early Homo sapiens, our faces strongly resemble those of our early ancestors.

Until this remarkable find at Jebel Irhoud, the oldest human fossils only dated back 195,000 years. These new fossils make experts believe that our species evolved not in Eastern Africa (specifically near Ethiopia) where later fossils were found, but across the continent in Western Africa where modern Morocco is situated.

We did not evolve from a single cradle of mankind somewhere in East Africa, paleoanthropologist Phillipp Gunz, a co-author of the two new studies on the fossils, told The New York Times.

Before now, fossils found in different places made paleoanthropologists believe that Homo sapiens arose in East Africa and then moved across the continent. However, mysterious human fossils from other parts of Africa didnt seem to fit in with this story, and caused scientists to wonder where they fit into the Homo sapiens puzzle. The remains discovered in Morocco will helpsolve these mysteries, even as it suggests new questions for further research.

For example, the recent finds at Jebel Irhoud confirm that Homo sapiens had flatter faces, similar to ours today. National Museum in London paleoanthropologist Christopher Stringer speculates that the flattened faces of early Homo sapiens may be related to the advent of speech. We really are at very early stages of trying to explain these things, Dr. Stringer told theThe New York Times.

The larger, rounder brain of modern humans is a more recent development. Dr. Gunz indicates that the human brain may have evolved into a rounder shapeduring a later phase of human existence. Two areas of the brain in particular the cerebellum and the parietal lobe, both toward the back of the head seem to have adapted over thousands of years. That being said,scientists dont yet know how the rounder brain changed how humans think.

Flint blades from around the same time have been found elsewhere across Africa, and the Jebel Irhoud fossils suggest that they may have been made by early humans. Dr. Gunz and his team believe that is this is true: Homo sapiens may have evolved across the continent as a network of groups. The only way well ever know for sure and resolve other questions these findings may bring up will bethrough additional research, which will require adequate funding.

See original here:

New Discovery of the Oldest Known Human Remains Will Change the Narrative of Human Evolution - Futurism

Scientists Finally Witnessed a Phenomenon That Einstein Thought Impossible – Futurism

In Brief Astronomers have observered a phenomenon known as gravitational microlensing in stars for the first time. Predicted by Einstein as part of his theory of general relativity, this could help measure the mass of distant stars using gravitational deflection. Celestial Warping

According to Einsteins general relativity theory, spacetime bends or gets distorted when it crosses a massive object due to its gravity. In the same manner, Einstein theorized that such a distortion also happens tolight from a distant star when it passes another star along a line of sight from Earth like a near stellar eclipse, so to speak. In this case, gravity should act as a magnifying lens by brightening and bending the light from the distant star, warping its apparent position.

Einstein, however, wasnt particularly confident about ever seeing such this gravitational deflection of starlight. In an article published in Sciencein 1936, he said that because stars are so distant from one another there is no hope of observing this phenomenon directly. An international team of researchers, however, have just proven Einstein wrong but also right by seeing a type of gravitational microlensing from a star other than the Sun.

The team, led by Kailash Sahu from the Space Telescope Science Institute, reported their findings in a new studypublished in the same journal.Einstein would be proud, Terry Oswalt saidin an interview with Wired. One of his key predictions has passed a very rigorous observational test.

Sahus team used the Hubble Space Telescope with its superior angular resolution to measure the shifts in a distant background stars apparent position around a nearby white dwarf star called Stein 2051 B as its light was deflected. The observations were made on eight dates in a two year period, between October 2013 and October 2015.

In the same way that a 1919 total solar eclipse provided the first observations of starlight curving and gave the initialconvincing proofs of Einsteins general theory of relativity, the new study confirms it anew. It also gave Sahus team a way to measure the mass of the foreground white dwarf star, which was previously unmeasurable.

The astrometric lensing approach used by Sahu et al. can be used equally well for any other nearby stars that happen to pass in front of background stars, Oswalt wrote in a perspective article in Science. In the coming era of truly massive sky surveys such as the Large Synoptic Survey Telescope, astronomers are bound to observe other similar events, despite their rarity.

Go here to read the rest:

Scientists Finally Witnessed a Phenomenon That Einstein Thought Impossible - Futurism

Blazing a Trail: Hawaii Becomes the First US State to Commit to the Paris Climate Accords – Futurism

In Brief The government of Hawaii signed two bills on Tuesday which formalizes its commitment to the goals of the Paris Climate Agreement. This comes after U.S. President Donald Trump decided to pull out of the climate deal.

Tuesday was a historic moment for Hawaii as it became the first state in the U.S. to make its stand on the Paris Climate Agreement formal. The Pacific state signed two bills to honor the climate deal after the federal governments decision to withdraw from it. In his statement during the signing of the two bills, Hawaii governor David Ige said that hes looking forward to working with other states to fight global climate change.

Governor Ige signed Senate Bill 559 which would ensure statewide support for Hawaiis green initiatives and to further theStates commitment to combat climate change by systematicallyreducing and mitigating greenhouse gas emissions through theenactment of principles that mirror many of the provisions adopted in the Paris Agreement.

The governor also signed House Bill 1578, which creates a task force to help keep Hawaiis soil and air clean. It would identify agricultural and aquacultural practices to improve soil health and promote carbon sequestration the capture and long-term storage of atmospheric carbon dioxide to mitigate climate change.

Hawaii isnt the only state that pledged to uphold the guidelines set by the Paris Agreement. Several governors and a dozen mayors across the U.S. have promised to do the same. The Hawaii State Legislature understands the importance of taking action, and I applaud its work this session to ensure that we continue to deliver the island Earth that we want to leave to our children, Ige said.

Go here to read the rest:

Blazing a Trail: Hawaii Becomes the First US State to Commit to the Paris Climate Accords - Futurism

Mark Cuban Asserts That Bitcoin is Not Currency – Futurism

In BriefMark Cuban has attacked Bitcoin on Twitter, claiming it is nota currency, it is a bubble, and that the whole system of valuationconcerning it is wrong. But is he right? Mark Cubans Twitterstorm

Mark Cuban has recently raised a series of criticisms of bitcoin on Twitter, which has resulted in the cryptocurrencys exchange rate dropping rapidly illustrating many of the issues with the currency that he discussed in the Tweet themselves.

Mark Cuban rose to wealth by selling his start-up businesses MicroSolutions (a PC company that he sold to CompuServe for $6 Million) and Broadcast.com (which transmitted sports games over the internet, and was subsequently sold to Yahoo for $5.7 Billion) in the 1990s, and rose to prominence by becoming owner of the NBA team the Dallas Mavericks.

Earlier today he took his opinions of Bitcoin toTwitter:

Cuban crucially differentiates between blockchain and Bitcoin: the former being a means of transaction that is more secure, transparent, and distributive, and the latter a cryptocurrency.

However, Cuban likens bitcoin to the religious worship of gold as an asset and describes it as a stock, which is fundamentally different from a currency currencies measure how much of an asset you have. This is why Cuban progresses to state I am not questioning value. Im questioning valuation.

Just because bitcoins exchange rate has reached thousands of dollars, this doesnt mean that anyone would be willing to give you thousands of dollars for your bitcoin. Currencies are universal measures of value in the country you operate which allows anyone to trade with anyone as part of a universal system of value. This is in contrast to assets which you can buy with that value system but not necessarily trade anywhere as easily.

Currencies, in order to operate in this way, need to be relatively stable which Cuban showed bitcoin was not due to the almost instant drop after his tweetstorm. To analogise: can you imagine the dollar, pound, or euro drastically dropping in a matter of hours just because of a few tweets?

On the surface, Bitcoin looks monumentally impressive: it has grown every year apart from 2014, has climbed 141 percent in value this year alone, even peaking at $2,900 this past week. However, the precise reason for this success is the reason for its potential failure it is too turbulent, too successful.

This means that while Bitcoin may seem extremely seductive it has been billed as, among other things, the ultimate investment and a universal currency we must be careful when investing in it (particularly because it is difficult to convert back into dollars), putting faith in it, and being overoptimistic about its potential.

Bitcoin is one particularly famous use of a potentially more promising and widely applicable system called blockchain, which has the potential to revolutionize everything from the music industry to sustainable development and even banking accountability.

According to many, it is blockchain, not bitcoin, that has the potential to revolutionize future transactions: If the internet bought us near instant digital communication, then the blockchain brings us near instant asset transfer, asset movement and security of data movement said Simon Taylor, the previous head of Barclays cryptocurrency division.

Read the original:

Mark Cuban Asserts That Bitcoin is Not Currency - Futurism

Here’s Everything You Missed From Tesla’s Annual Shareholder Meeting – Futurism

In BriefTesla's annual shareholders meeting took place yesterday, andfor many, the highlight of the event was CEO Elon Musk taking thestage. In addition to answering questions from Twitter, hedelivered updates on several forthcoming Tesla projects. An Annual Update

Tesla founder and CEO Elon Musk is a showman, perhaps on par withApples Steve Jobs when it comes to big reveals during public appearances.

His usual platform is Teslas annual shareholder meeting, but yesterday, he didnt deliver much by way of reveals. Still, Musk didpaint the general direction Tesla would be taking in the next several months while addressing the shareholders and responding to questions from Twitter.

If you missed the livestream of the presentation, dont fret. Heres everythingyou need to know from it.

Musk mentioned three upcoming vehicles that Tesla has been working on: the Model 3, the Model Y, and an electric semi truck (that last ones so exciting it deserved an article all to itself).

The Model 3 is expected to be releasedby the end of the month, andMusk emphasized the vehicles relative simplicity. I should say that weve kept the initial configurations of the Model 3 very simple, said the CEO. A big mistake we made with the X, which is primarily my responsibility there was way too much complexity right at the beginning. That was very foolish.

Attendees were then treated toa first look at the Model Y, Teslas electric crossover SUV. Theimage is decidedly lacking in detail, so we still have very little to go on with this model, but we do know that its slated for a 2019 release and would be built on a completely new platform. In fact, Tesla would build an entirely new factory for its production.

Oh, and an electric plane somewhere down the road is also not inconceivable, according to Musk.

Musk also offered updates on Teslas Autopilot, claiming that the company will be rolling out improvements to the system for its Hardware 2 vehicles. Since its split with Mobileye the Israeli software maker responsible for the earlier versions of Teslas self-driving system Tesla has been developing its own semi-autonomous software. While some consumers have had some issues with the autonomous system in Teslas new vehicles, Musk said that its now almost better than the Mobileye version.

Usually, after Musk points out a problem, he shares a solution for it(see: traffic and the Boring Company). At yesterdays meeting, Musk shared his criticisms of todays music algorithms and playlist quality, and in typical Musk fashion, he plans to do something about it. He says Tesla will release a music service or feature later this year, and its gonna be the music you want to listen to.

After being asked about how he spends his time, Musk made reference to his late-night tweets. He admitted that he would sometimes go crazy on Twitter, but he blames it on music, wine, and a sedative. You know, [when] theres a little red wine, a vintage record player, some Ambien. Magic. Magic happens, he said, later echoing the sentiment (where else?) in a tweet.

Musk also explained that he generally spends 90 percent of his time working on Tesla and SpaceX, whiledividing therest betweenNeuralink (3 to 5 percent), the Boring Company (2 percent), and Open AI (less than 2 percent).

Like a true showman, Muskwas sure toinclude a cliffhanger in his presentation to keep the people wanting mroe. Theres a few other things I havent mentioned here. I just like, really recommend showing up for the semi truck unveiling, he said. Maybe theres a little more than were saying here. Maybe. Could be. Who knows?

Continued here:

Here's Everything You Missed From Tesla's Annual Shareholder Meeting - Futurism

An AI Can Now Predict How Much Longer You’ll Live – Futurism

In Brief Researchers at the University of Adelaide have developed an AI that can analyze CT scans to predict if a patient will die within five years with 69 percent accuracy. This system could eventually be used to save lives by providing doctors with a way to detect illnesses sooner. Predicting the Future

While many researchers are looking for ways to use artificial intelligence (AI) to extend human life, scientists at the University of Adelaidecreated an AI that could help them better understand death. The system they created predicts ifa person will die within five years after analyzingCT scans of their organs, and it was able to do sowith 69 percent accuracy a rate comparable to that of trained medical professionals.

The system makes use of thetechnique of deep learning, and it was tested using images taken from 48 patients, all over the age of 60. Its the first study to combine medical imaging and artificial intelligence, and the results have been published in Scientific Reports.

Instead of focusing on diagnosing diseases, the automated systems can predict medical outcomes in a way that doctors are not trained to do, by incorporating large volumes of data and detecting subtle patterns, explained lead authorLuke Oakden-Rayner in a university press release. This method of analysis can explore the combination of genetic and environmental risks better than genome testing alone,according to the researchers.

While the findings are only preliminary given the small sample size, the next stage will apply the AI to tens of thousands of cases.

While this study does focus on death, the most obvious and exciting consequence of it is how it could help preserve life. Our research opens new avenues for the application of artificial intelligence technology in medical image analysis, and could offer new hope for the early detection of serious illness, requiring specific medical interventions, said Oakden-Rayner. Because it encourages more precise treatment using firmer foundational data, the system has the potential to save many lives and provide patients with less intrusive healthcare.

An added benefit of this AI is its wide array of potential uses. Because medical imaging of internal organs is a fairly routine part of modern healthcare, the data is already plentiful. The system could be used to predict medical outcomes beyond just death, such as the potential for treatment complications, and it could work with any number of images, such as MRIs or X-rays, not just CT scans. Researchers will just need to adjustthe AItotheir specifications, andtheyll be able to obtain predictions quickly and cheaply.

AIsystems are becoming more and more prevalentin the healthcare industry.Deepmind is being usedto fight blindness in the United Kingdom, and IBM Watson is already as competent as human doctors at detecting cancer. It is in medicine, perhaps more than any other field, that we see AIs huge potential to help the human race.

Read the rest here:

An AI Can Now Predict How Much Longer You'll Live - Futurism

New Research Shows That Cannabinoids Can Help Treat Leukemia – Futurism

In Brief Researchers from St. George's, University of London have found that combining chemotherapy with cannabinoids can effectively treat leukemia. Though the tests were done in vitro, it showed that it could potentially lower the needed dose for chemo. Working in Tandem

Theres a growing literature of research showcasing the supposed health benefits of cannabis, specifically its active chemicals like cannabinoids. These have gone to cover various diseases, most notably brain-related ones such as epilepsy, Alzheimers, dementia, as well as heart problems and cancer. One study even claims that cannabis could potentially reverse aging. Now, researchers from St Georges, University of London have found cannabinoids to be effective in treating leukemia.

Specifically, the research involved using phytocannabinoids the naturally-occurring cannabinoids in the cannabis plant in tandem with chemotherapy. Phytocannabinoids possess anticancer activity when used alone, and a number have also been shown to combine favorably with each other in vitro in leukaemia cells to generate improved activity, according to a study published in the International Journal of Oncology.

Though the tests were done in the laboratory, the researchers are confident that combining phytocannabinoids with chemotherapy for leukemia patients could mean lower doses for the latter effectively lessening its side-effects.

As with most studies involving cannabis, its worth mentioning that its not possible to achieve the effects claimed by the study by recreational use of the drug. These extracts are highly concentrated and purified, so smoking marijuana will not have a similar effect, lead researcher Wai Liu said in a press release. But cannabinoids are a very exciting prospect in oncology, and studies such as ours serve to establish the best ways that they should be used to maximize a therapeutic effect.

With cancers continuing prevalence, research into potential treatments have become rather creative over the past years. Gene therapy is, perhaps, the most popular and other explore the use of nanoparticles. The strangest of these potential treatments is in an anti-cancer drug-delivery mechanism courtesy of sperm cells. At any rate, for a fight against one of the worlds deadliest diseases, we need all the help we could get.

The rest is here:

New Research Shows That Cannabinoids Can Help Treat Leukemia - Futurism

President Trump Tells Evangelical Supporters: ‘We’re Under Siege’ – TIME

U.S. President Donald Trump speaks during the Faith & Freedom Coalition's Road to Majority Conference June 8, 2017 in Washington, DC. Alex WongGetty Images

(WASHINGTON) President Donald Trump sought comfort in the figurative embrace of his evangelical supporters Thursday as the FBI director he recently fired told Congress about their conversations. The president told a religious gathering that "we're under siege" but will emerge "bigger and better and stronger than ever."

Trump made no reference to James Comey in his remarks to the Faith and Freedom Coalition's annual gathering. But hours before the president's first public comments of the day, Comey told the Senate intelligence committee that Trump tried to get him to pledge loyalty and drop an investigation into former National Security Adviser Michael Flynn.

Trump abruptly fired Comey last month. Trump's attorney said the president never asked Comey to stop investigating anyone.

In his remarks to the conference, Trump pledged to always support the right of evangelicals to follow their faith, which some conservatives believe is under attack by government.

"We will always support our evangelical community and defend your right and the right of all Americans to follow and to live by the teachings of their faith," the president told more than 1,000 activists meeting at a hotel across town from Capitol Hill, the scene of Comey's nationally televised testimony.

"And as you know, we're under siege, you understand that. But we will come out bigger and better and stronger than ever. You watch," Trump said. "You fought hard for me and now I'm fighting hard for all of you."

Trump spoke about his actions to safeguard religious freedom and continued, for the second straight day, to label congressional Democrats as "obstructionists" who are blocking his agenda. Yet it is differences of opinion among Republicans, who control both houses of Congress, that are standing in the way of what Trump wants to do on health care and other issues.

Trump mentioned his nomination of federal judge Neil Gorsuch to the Supreme Court, which pleased Christian conservatives. He also has directed the IRS to ease up on using a rarely enforced rule barring partisan political activity by churches and tax-exempt organizations.

"As long as I'm president, no one is going to stop you from practicing your faith or preaching what is in your heart," he said.

Trump won an overwhelming 80 percent of the white evangelical vote in the November election. A recent Pew Research Center survey marking his first 100 days in office found three-fourths of white evangelicals approved of his performance as president. Thirty-nine percent of the general public held the same view.

Trump said restoring freedom also meant repealing and replacing the health care law enacted in 2010 by then-President Barack Obama, saying high deductibles and premiums have turned it into a "catastrophe." But a replacement health care bill has yet to clear Congress despite seven years of pledges by Republicans to scrap the law and start over, and despite the fact that the GOP has full control of the White House and Congress.

The Republican-controlled House passed a bill with the bare minimum of GOP votes and none from Democrats. Senate Republicans are working on their version of the bill, but are divided about the approach.

Trump overlooked the intraparty squabbles and blamed Democrats. He said Democrats have gone so far to the left in terms of opposing him that "they're bad right now for the country." Democrats oppose dismantling Obama's health law.

The president urged the audience to help send more Republicans to Congress in next year's midterm elections, noting the GOP has just a 52-48 edge in the Senate and a slim advantage in the House.

"We have to build those numbers up because we're just not going to get votes" from Democrats, he said. "Sadly, we're going to have to do it as Republicans because we're not going to get any Democrat votes and that's a very, very sad, sad thing."

Trump ignored the fact that three Democratic senators voted to put Gorsuch on the Supreme Court.

See the original post:

President Trump Tells Evangelical Supporters: 'We're Under Siege' - TIME

It’s not the ‘Freedom Caucus.’ It’s the Billionaires’ Caucus. – The Hill (blog)

The answer is simple: the Freedom Caucus is made up of 31 ultra-conservative members of Congress whose primary purpose is to defend the interests of the super-rich.

And they deserve a new name: the Billionaires Caucus.

The evidence for this new nomenclature spans the key issues up for debate in Washington this summer.

On TrumpCare, the Freedom Caucus forced amendments to eliminate protections for Americans with pre-existing conditions and requirements that made sure families who pay their insurance premiums actually get a basic package of services and care.They slashed funding to state governments and jacked up premiums for seniors.But they gave the green light to billions in tax breaks for the wealthiest members of our society.

Who benefitted? Only the billionaires.

The same is true for tax policy and the budget more broadly.

President Trump has major corporations and their CEOs salivating over a proposed tax overhaul that would dramatically reduce taxes for corporations and billionaires and actually increase taxes on working-class families.And when President Trump vowed in his budget proposal to cut safety net programs including food stamps, Medicaid, and public benefits by over $1 trillion, it was geared precisely at appeasing these legislators and their base.

The outcome of these tax and budget proposals is obvious: it would redistribute income from poor and working-class Americans up to the ultra-wealthy.On taxes and budgets, this caucus is putting points on the board -- for the billionaires.

And while these "freedom-loving" legislators claim to oppose virtually all forms of government regulation, theyre quite happy to support renewed discrimination and enormous government investments in controversial immigration policies and Trumps proposed border wall.

Aside from being a symbol of intolerance and division, Trumps wall is really a symbol of government largesse and waste.True libertarians would oppose it on these grounds, but these legislators support it.

Similarly, their legislation to make voting harder for communities of color, young people, and low-income people is an example of big government cutting off the rights of regular people.

Its clear that Caucus members need to deliver government policies that satisfy racialized anti-immigrant sentiments among the Republican base, in order to provide a smokescreen for their pro-billionaire tax and budget policies that hit working-class voters hard.

Nicknames in politics sometimes come from politicians themselves, but the more accurate ones come from savvy observers.

The Freedom Caucus is Orwellian double-speak.

From now on, lets call them these lapdogs of the ultra-rich what they are: the Billionaires Caucus.

The views expressed by this author are their own and are not the views of The Hill.

Continue reading here:

It's not the 'Freedom Caucus.' It's the Billionaires' Caucus. - The Hill (blog)

Myanmar protest for journalistic freedom underway – Christian Science Monitor

June 8, 2017 Yangon, MyanmarMyanmar journalists sporting "Freedom of the Press" armbands gathered on Thursday to campaign against a law they say curbs free speech, at the start of a trial of two journalists who the Army is suing for defamation over a satirical article.

The rally by more than 100 reporters in the rain outside a court in Yangon was the first significant show of opposition to the telecommunications law, introduced in 2013, that bans the use of the telecoms network to "extort, threaten, obstruct, defame, disturb, inappropriately influence, or intimidate."

Despite pressure from human rights monitors and Western diplomats, the government of Aung San Suu Kyi, which took power amid high hopes for democratic reform in 2016, after decades of hardline military rule, has retained the law.

The journalists said they were dismayed by the recent arrests of social media users whose posts were deemed distasteful, as well as of journalists critical of the military.

"At first, they were suing people over news articles and now they are suing even over a satirical article, showing how they are restricting the media," said A Hla Lay Thuzar, one of the founders of the Protection Committee for Myanmar Journalists, which organized the rally.

She said that rather than staging a one-off protest, her group wants to launch a movement to raise public awareness of the issue and press the government to abolish the law.

The journalists on trial are the chief editor and a columnist of the Voice, one of Myanmar's largest dailies.

They were denied bail on the first day of their trial, meaning they may have to remain in custody.

"Obtaining bail is our right so we will keep fighting for it during next court dates until we get it," said Khing Maung Myint, who is representing the two journalists.

The telecommunications law was a main piece of legislation introduced by a semi-civilian administration of former generals which navigated Myanmar's transition from full military rule to the coming to power of Ms. Suu Kyi's government, from 2011 to 2016.

The protesting journalists said they would wear the armbands for the next 10 days to raise awareness about what they see as the threat to freedom of the press.

They are also planning to gather signatures for a petition to abolish the law, to be sent to Suu Kyi's office, the Army chief and parliament.

Read more here:

Myanmar protest for journalistic freedom underway - Christian Science Monitor

News poem: Greg Abbott can smell freedom – Houston Chronicle

Texas Gov. Greg Abbott said, "Once you cross the Travis County line, it starts smelling different. And you know what that fragrance is? Freedom."

Texas Gov. Greg Abbott said, "Once you cross the Travis County...

Earlier this week, Gov. Greg Abbott said to a group of rural Republicans, "Once you cross the Travis County line, it starts smelling different. And you know what that fragrance is? Freedom. It's the smell of freedom that does not exist in Austin, Texas."

There's a lot that Abbott doesn't like about Austin, but one of his main complaints is that it's a sanctuary city, which is the inspiration for this poem. He and I have different ideas of what freedom means.

I have lived with an anxiety disorder for decades. It comes and goes, it has changed some, but it will always be a defining part of my personality and the way I experience life. I know it when I see it, and a lot of people are experiencing anxiety this year in this political climate.

I ask you to put yourself in the shoes of immigrant families -- citizens or undocumented -- who are anxious right now in Texas. Think about the children who know something is wrong, but don't fully understand what it is. I feel for them. I wish Greg Abbott could do the same.

'The Smell of Freedom'

When I was small, I was afraid. A square peg wedged into darkness, nothing clicked: No hand fit my hand, no calm could reach my timorous skin. So I hit myself nightly, giving myself bruises, soothing buttons to press the next day.

Children are eaten away by mystery. Shadows that aren't quite monsters look like people, smile like people, but have a secret plan to crack them open, send their yolk away.

And you would have them running like stray dogs as you sniff the air, shoot the sky, claim another star for your hat. But that smell is not freedom. It is fear burning hot in pockets. It is the sweat-drenched uniforms of people trying just to pass. It is a fire that you set as you burn your name across the state.

Gov. Abbott: Austin stinks and so does 'Sanctuary Sally' Austin American-Statesman

Sara Cress (@saracress) is a writer in Houston. For her poems and to buy her books see her website, Breaking Poems.

Bookmark Gray Matters and claim another star for your hat.

To read this article in one of Houston's most-spoken languages, click on the button below.

Get Gray Matters sent to your inbox. Sign up now!

More here:

News poem: Greg Abbott can smell freedom - Houston Chronicle

Israel’s commitment to press freedom questioned after journalist shot – The Jerusalem Post


The Jerusalem Post
Israel's commitment to press freedom questioned after journalist shot
The Jerusalem Post
The Foreign Press Association (FPA) in Israel on Wednesday called into question Israel's commitment to protecting civilians and ensuring freedom of the press. The FPA's statement follows the wounding of an Associated Press photographer by an Israeli ...

See the original post:

Israel's commitment to press freedom questioned after journalist shot - The Jerusalem Post